跳至主要内容
临床试验/NCT03752996
NCT03752996已完成不适用

ACURATE TF™ Transfemoral Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis

Symetis SA10 个研究点 分布在 2 个国家目标入组 140 人开始时间: 2012年5月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
140
试验地点
10
主要终点
Freedom from all-cause mortality

研究概览

简要总结

First-In-Man Study on the ACURATE TF™ Transfemoral Aortic Bioprosthesis Implantation in Patients with Severe Aortic Stenosis to collect human feasibility data pertaining to the safety and performance of the device.

详细描述

A single arm, prospective, multicenter, non-randomized, open trial, up to 5 Years follow-up with the Symetis ACURATE TF™ Transfemoral Aortic Bioprosthesis for minimal invasive implantation via transfemoral access to treat patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open heart surgery is considered to be associated with high risk.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
75 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients 75 years of age and older
  • Logistic EuroSCORE ≥ 20%
  • Severe aortic stenosis characterized by mean aortic gradient > 40 mmHg or peak jet velocity > 4.0 m/s or aortic valve area < 1.0 cm2
  • New York Heart Association (NYHA) Functional Class > II
  • Aortic annulus diameter from ≥ 21mm up to ≤ 27mm measured by TEE
  • Patient not a surgical candidate due to significant co-morbid conditions unrelated to aortic stenosis
  • Patient willing to participate in the study and provide signed informed consent

排除标准

  • Unicuspid or bicuspid aortic valve
  • Extreme eccentricity of calcification
  • Severe mitral regurgitation ( >2+)
  • Pre-existing prosthetic heart valve in any position and / or prosthetic ring
  • Aortic or peripheral anatomy NOT appropriate for transfemoral implant
  • Thoracic (TAA) or abdominal (AAA) aortic aneurysm
  • Presence of endovascular stent graft for treatment of TAA or AAA
  • Trans-esophageal echocardiogram (TEE) is contraindicated
  • Left Ventricle Ejection Fraction (LVEF) < 30% by echocardiography (ECHO)
  • ECHO evidence of intracardiac mass, thrombus, or vegetation
  • Acute Myocardial Infarction (AMI) within 1 month prior to implant procedure
  • Percutaneous Coronary Intervention (PCI), except for balloon valvuloplasty (BAV) within 1 month prior to implant procedure
  • Previous Transient Ischemic Attack (TIA) or stroke within 3 months prior to implant procedure
  • Active ulcer or gastrointestinal (GI) bleeding within 3 months prior to implant procedure
  • Any scheduled surgical or percutaneous procedure to be performed prior to 30 day visit
  • History of bleeding diathesis or coagulopathy or refusal of blood transfusions
  • Systolic pressure <80 mmHg, cardiogenic shock, need for inotropic support or Intra-Aortic Balloon Pump (IABP)
  • Primary hypertrophic obstructive cardiomyopathy (HOCM)
  • Active infection, endocarditis or pyrexia
  • Hepatic failure
  • Chronic renal dysfunction with serum creatinine > 2.5 mg/dL or renal dialysis
  • Refusal of surgery
  • Severe Chronic Obstruction Pulmonary Disease (COPD) requiring home oxygen
  • Neurological disease severely affecting ambulation or daily functioning, or dementia
  • Life expectancy < 12 months due to non-cardiac co-morbid conditions
  • Known hypersensitivity/contraindication to study medication, contrast media, or nitinol
  • Currently participating in an investigational drug or another device study

结局指标

主要结局

Freedom from all-cause mortality

时间窗: 30-Days

Rate of all-cause mortality

次要结局

  • Rate of MACCE (major cardiac and cerebrovascular event)(30-Days and 12-Months)

研究者

发起方
Symetis SA
申办方类型
Industry
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验